Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2b trial of intracoronary MYDICAR in chronic systolic heart failure
NL-OMON39413Phase 2Active, not recruiting
- Sponsor
- Celladon Corporation
- Start
- Aug 2013
- Modality
- Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in heart failure with reduced ejection fraction (HFrEF), ischaemic cardiomyopathy (ICM) and dilated cardiomyopathy (DCM) comparing MYDICAR with Placebo (2 arms). Started Aug 2013; status: active, not recruiting.
02
Drugs
AAV1/SERCA2a
03
Conditions
heart failure with reduced ejection fraction (HFrEF)ischaemic cardiomyopathy (ICM)dilated cardiomyopathy (DCM)
Beyond the preview
Go deeper on NL-OMON39413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39413.